GlassScriptPhysician profile
Manjot Kang
NPI 1427057207
$8,763.68
in general payments reported to CMS, 2019-2025
42 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $847 · 2021: $1,110 · 2022: $1,432 · 2023: $1,394 · 2024: $1,514 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,703 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,702.67 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $849.65 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $795.84 | 2019-2025 | |
| Lilly USA, LLC | $782.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $761.23 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $629.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $388.33 | 2022-2024 | Xifaxan, Trulance |
| Amgen INC. | $348.19 | 2019-2025 | Otezla, Repatha, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $347.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.67 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $321.58 | 2019-2024 | Spravato |
| Abbott Laboratories | $288.56 | 2021-2025 | Freestyle Libre 3 |
| Olympus America INC. | $150.71 | 2025 | Itind System |
| Astellas Pharma US INC | $135.26 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $100.94 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjot Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.